Kontush Anatol, Chapman M John
INSERM Unité 551, Pavillon Benjamin Delessert, Hôpital de Pitié, 83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Curr Diab Rep. 2008 Feb;8(1):51-9. doi: 10.1007/s11892-008-0010-5.
High-density lipoprotein (HDL) particles exert a spectrum of atheroprotective activities that can be deficient in type 2 diabetes. Key mechanisms leading to the formation of functionally deficient HDL involve 1) HDL enrichment in triglycerides and depletion in cholesteryl esters with conformational alterations of apolipoprotein A-I; 2) glycation of apolipoproteins and/or HDL-associated enzymes; and 3) oxidative modification of HDL lipids, apolipoproteins, and/or enzymes. Available data identify hypertriglyceridemia, with concomitant compositional modification of the HDL lipid core and conformational change of apolipoprotein A-I, as a driving force in functional alteration of HDL particles in type 2 diabetes. Therapeutic options for correcting HDL functional deficiency should target hypertriglyceridemia by normalizing circulating levels of triglyceride-rich lipoproteins.
高密度脂蛋白(HDL)颗粒具有一系列抗动脉粥样硬化活性,而2型糖尿病患者体内这些活性可能不足。导致功能性缺陷HDL形成的关键机制包括:1)甘油三酯在HDL中富集,胆固醇酯减少,同时载脂蛋白A-I发生构象改变;2)载脂蛋白和/或与HDL相关的酶发生糖基化;3)HDL脂质、载脂蛋白和/或酶发生氧化修饰。现有数据表明,高甘油三酯血症以及伴随的HDL脂质核心成分改变和载脂蛋白A-I构象变化是2型糖尿病患者HDL颗粒功能改变的驱动力。纠正HDL功能缺陷的治疗选择应通过使富含甘油三酯的脂蛋白循环水平正常化来针对高甘油三酯血症。